We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
In the latest trading session, Gilead Sciences (GILD - Free Report) closed at $65.39, marking a +0.17% move from the previous day. This change outpaced the S&P 500's 0.06% loss on the day. At the same time, the Dow lost 0.1%, and the tech-heavy Nasdaq lost 0.1%.
Coming into today, shares of the HIV and hepatitis C drugmaker had gained 0.76% in the past month. In that same time, the Medical sector lost 2.31%, while the S&P 500 gained 4.3%.
Investors will be hoping for strength from GILD as it approaches its next earnings release, which is expected to be May 2, 2019. The company is expected to report EPS of $1.61, up 8.78% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $5.29 billion, up 4.03% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $6.64 per share and revenue of $22.01 billion. These totals would mark changes of -0.45% and -0.55%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for GILD. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. GILD is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, GILD is currently trading at a Forward P/E ratio of 9.82. For comparison, its industry has an average Forward P/E of 21.57, which means GILD is trading at a discount to the group.
We can also see that GILD currently has a PEG ratio of 3.85. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 2 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 55, which puts it in the top 22% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
In the latest trading session, Gilead Sciences (GILD - Free Report) closed at $65.39, marking a +0.17% move from the previous day. This change outpaced the S&P 500's 0.06% loss on the day. At the same time, the Dow lost 0.1%, and the tech-heavy Nasdaq lost 0.1%.
Coming into today, shares of the HIV and hepatitis C drugmaker had gained 0.76% in the past month. In that same time, the Medical sector lost 2.31%, while the S&P 500 gained 4.3%.
Investors will be hoping for strength from GILD as it approaches its next earnings release, which is expected to be May 2, 2019. The company is expected to report EPS of $1.61, up 8.78% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $5.29 billion, up 4.03% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $6.64 per share and revenue of $22.01 billion. These totals would mark changes of -0.45% and -0.55%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for GILD. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. GILD is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, GILD is currently trading at a Forward P/E ratio of 9.82. For comparison, its industry has an average Forward P/E of 21.57, which means GILD is trading at a discount to the group.
We can also see that GILD currently has a PEG ratio of 3.85. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 2 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 55, which puts it in the top 22% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.